Test Price
850 AED✅ Home Collection Available
FISH for inv(16) / CBFB Gene Rearrangement Test in UAE | 850 AED | 2026 DHA Guidelines
تحليل FISH للانقلاب 16 / جين CBFB في الإمارات | 850 درهم | معتمد من هيئة الصحة بدبي
يقدم هذا الاختبار الجيني المتطور تشخيصًا دقيقًا لسرطان الدم النخاعي الحاد باستخدام تقنية التهجين الفلوري الموضعي (FISH)، وفقًا لأحدث إرشادات هيئة الصحة بدبي لعام 2026، وباعتماد مختبر حاصل على شهادة الأيزو 9001:2015.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain, VIP Mobile Phlebotomy available 8 AM – 11 PM.
- Clinical Guidance: Complimentary post-test telephonic clinical correlation by DHA-certified specialists.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview
The FISH for inv(16)/CBFB gene rearrangement detects specific chromosomal abnormalities associated with acute myeloid leukemia (AML), particularly acute myelomonocytic leukemia with abnormal eosinophils. This fluorescence in-situ hybridization assay directly visualizes the CBFB gene break-apart or fusion signals on interphase cells from blood or bone marrow, delivering results within 4 working days. اختبار FISH للانقلاب 16 (جين CBFB) هو فحص جيني دقيق يستهدف التغيرات الكروموسومية المرتبطة بسرطان الدم النخاعي الحاد.
| Feature | Our FISH inv(16)/CBFB Test | Conventional Karyotyping |
|---|---|---|
| Precision | Single-cell resolution, detects cryptic rearrangements | Limited to metaphase cells; may miss submicroscopic inversions |
| Methodology | FISH using LSI CBFB break-apart probe (interphase/metaphase) | G-banding karyotype on cultured cells |
| Turnaround Time | 4 working days | 7–14 days |
| Sample Requirements | 3 mL whole blood or 2 mL bone marrow in sodium heparin (green top), non-frozen | Larger volume, sterile collection, transport at room temp |
Physician Insight & Safety Protocol
“As a DHA-licensed consultant hematologist, I emphasize that while the FISH inv(16)/CBFB test provides definitive genetic evidence, it must always be correlated with morphology, immunophenotyping, and clinical context. A positive result supports AML-M4Eo diagnosis but does not replace full diagnostic workup. Please use this test as part of a comprehensive evaluation.” – Dr. Prabhakar Reddy, DHA License 61713011.
⚠ Medication Warning
Do not discontinue prescribed chemotherapy or any medication without consulting your treating physician. Interpretation of this genetic test should be done by a qualified oncologist or hematologist.
Exclusion Criteria & Emergency Red Flags
- Severe bleeding tendency or platelet count < 20,000/μL (venipuncture risk).
- Active systemic infection with hemodynamic instability — postpone sampling.
- Inability to provide mandatory Form 17 (Chromosome & FISH Analysis Requisition).
- Sample frozen or exposed to temperature extremes — testing invalidated.
If you experience fever, uncontrolled bleeding, or sudden neurological changes after bone marrow aspiration, seek emergency care immediately.
Frequently Asked Questions
What does the FISH inv(16)/CBFB test detect?
This specifically identifies inversions or translocations involving chromosome 16 and the CBFB gene, which are defining genetic abnormalities in acute myeloid leukemia subtype M4Eo. يكشف هذا الاختبار عن انقلاب الكروموسوم 16 أو إعادة ترتيب جين CBFB، وهو مؤشر أساسي لسرطان الدم النخاعي الحاد من النوع M4Eo.
How should I prepare for the sample collection?
Fasting is not required, but you must complete the mandatory Chromosome & FISH Analysis Requisition Form (Form 17) and ensure the sample is collected in sodium heparin green-top tubes without freezing. لا يشترط الصيام، ولكن يجب تعبئة استمارة تحليل الكروموسومات والـ FISH (نموذج 17) وجمع العينة في أنابيب الهيبارين الخضراء دون تجميد.
What does a positive result mean for my treatment?
A positive result confirms the presence of the inv(16)/CBFB rearrangement, which classifies AML as favorable‑risk and guides targeted therapy decisions, including potential use of gemtuzumab ozogamicin. النتيجة الإيجابية تؤكد وجود إعادة الترتيب الجيني وتصنف سرطان الدم ضمن الفئة منخفضة الخطورة، مما يوجه العلاج المستهدف.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians